Smith & Nephew (LON:SN) was downgraded by analysts at HSBC to a “hold” rating in a research report issued on Tuesday. They currently have a GBX 1,500 ($19.60) price target on the stock, up from their prior price target of GBX 1,400 ($18.29). HSBC’s target price suggests a potential upside of 17.60% from the company’s current price.
A number of other analysts have also weighed in on SN. Deutsche Bank restated a “sell” rating on shares of Smith & Nephew in a research note on Tuesday, July 3rd. Numis Securities upped their target price on shares of Smith & Nephew from GBX 1,350 ($17.64) to GBX 1,480 ($19.34) and gave the stock an “add” rating in a research note on Thursday, July 26th. Finally, UBS Group lowered shares of Smith & Nephew to a “neutral” rating and cut their target price for the stock from GBX 1,470 ($19.21) to GBX 1,340 ($17.51) in a research note on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 1,413.83 ($18.47).
SN stock opened at GBX 1,275.50 ($16.67) on Tuesday. Smith & Nephew has a fifty-two week low of GBX 1,173 ($15.33) and a fifty-two week high of GBX 1,442 ($18.84).
Smith & Nephew Company Profile
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Read More: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.